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Summary Neutrophil accumulation within epithelial crypts and in the intestinal mucosa
directly correlates with clinical disease activity and epithelial injury in ulcerative colitis (UC).
Current advances have defined the mechanisms by which neutrophils are activated or migrate
across mucosal epithelia. A better understanding of this process will likely provide new
insights into novel treatment strategies for UC. Especially, activated neutrophils produce
reactive oxygen and nitrogen species within intestinal mucosa, which induce oxidative stress.
In clinically, we have succeeded to develop a novel granulocytes adsorptive apheresis therapy
for UC. In this article, we discuss current advances to define the role of neutrophils-dependent
oxidative stress in UC.
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Introduction
The incidence of ulcerative colitis (UC) is increasing
year by year in Japan. Although it is clear that genetic,
environmental, immunological factors affect the patho-
physiology of UC, the direct cause of this disease is still
unknown. One of the most prominent histological features
observed in UC is infiltration of neutrophils into the inflamed
mucosa. Disease activity in UC is linked to an influx of
neutrophils into the mucosa and subsequently into the
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intestinal lumen, resulting in the formation of so-called crypt
abscesses. In addition, circulating activated neutrophils, a
major source of inflammatory cytokines, are elevated with
increased survival time in active UC. More importantly in
the clinical field, several studies showed that granurocytes/
monocytes adsorptive apheresis therapy could induce the
remission stage especially in patients with steroid-refractory
and steroid-dependent moderate-to-severe UC. In this
review article, we would like to offer an up-date data on the
role of leukocytes, especially neutrophils, in UC.
Leukocyte and Vascular Endothelial Cell Interaction
The sequence of events in the extravasation of neutrophils
from the vascular lumen to the extravascular space is
divided into 1) margination and rolling, 2) adhesion and
transmigration, and 3) migration in interstitial mucosal
tissues towards chemotactic stimulants (Fig. 1), which are
regulated by the interaction of adhesion molecules located
on the surface of neutrophils and endothelial cells [1, 2].
With stimuli, such as various cytokines and inflammatory
mediators, neutrophils roll slowly on endothelial cells through
interactions between L-selectin and carbohydrate antigen on
neutrophils, and P- and E-selectin on endothelial cells.
Eventually, the neutrophils adhere strongly to endothelial
cells via CD11/CD18 glycoproteins and endothelial adhesion
molecules of immunoglobulin superfamily, including the
intercellular adhesion molecule 1 (ICAM-1) and the vascular
cell adhesion molecule 1 (VCAM-1). Their expression is
stimulated by molecule such as inflammatory cytokines and
lipopolysaccharide (LPS). After firmly binding to the endo-
thelial surface, the neutrophils transmigrate between cells
along the intercellular junction. Platelet endothelial cell
adhesion molecule 1 (PECAM-1), a cell-cell adhesion
molecule, is a likely candidate for mediating this process.
After passing the endothelial junctions, leukocytes are able
to cross the basement membrane by focally degrading it
with secreted collagenases. After extravasation, neutrophils
emigrate towards the site of intestinal mucosal injury along
a chemical gradient of chemotaxis. In UC, exogenous and
endogenous substances are able to act as chemotactic agents
for neutrophils including 1) cytokines especially interleukin-8
(IL-8), 2) soluble bacterial products, particularly peptides with
N-formyl-methionine termini, 3) components of complement
system, and 4) products of the lipoxygenase pathway of
arachidonic acid metabolism, particularly leukotriene B4.
Current data suggests that Toll-like receptors (TLR), which
recognize specific pathogen-associated molecular patterns
(PAMPs), are differentially expressed on both leukocytes
and mucosal epithelial cells while serving to modulate
leukocyte-epithelial interactions. Exposure of epithelial
TLRs to microbial ligands has been shown to result in
transcriptional upregulation of inflammatory mediators
whereas ligation of leukocyte TLRs modulates specific anti-
microbial responses. A better understanding of these events
will hopefully provide new insights into the mechanisms of
epithelial responses to microorganisms and ideas for therapies
aimed at inhibiting the deleterious consequences of mucosal
inflammation in UC.
Neutrophil-Dependent Mucosal Injury
Neutrophils contain two major granule population, primary
(azunophil) and secondary (specific) granules, which are
Fig. 1. Neutrophil-endothelial interaction mediated by adhesion molecules and chemical mediatorsY. Naito et al.
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formed at different stages of neutrophil maturation. Primary
granules contain, as their main constituents, several pro-
teolytic enzymes and a wide range of bactericidal proteins
including cathepsin G, elastase, myeloperoxidase (MPO),
and lysozyme. The secondary granules contain a wide variety
of different components, including lactoferrin, lysozyme,
collagenase, and lipocalins. In activated neutrophils,
NADPH oxidase in cell membranes becomes activated, and
an electron transfer takes place from NADPH in cells to
oxygen inside and outside cells, and the oxygen that
received electrons becomes superoxide radicals (O2−˙),
which is rapidly converted to hydrogen peroxides (H2O2) by
spontaneous dismutation or enzymatic superoxide dismutase
(SOD), and hydroxyl radicals (˙OH), which are formed
nonenzymatically in the presence of Fe2+ as a secondary
reaction [3, 4].
Reactive oxygen species (ROS) are highly reactive. When
they are generated close to cell membranes, possibly by
intestinal epithelial cells, they induce oxidative stress and
oxidized membrane phospholipids (lipid peroxidation),
which may continue in a form of a chain reaction. Bio-
membranes contain large amounts of polyunsaturated fatty
acids (PUFAs) in their phospholipids. PUFAs contain two or
more carbon-double bonds within their structure. This
makes them susceptible to oxidative damage by free radical
attack, which is a direct cell injury induced by oxidative
stress. PUFAs of cell membranes are degraded by lipid
peroxidation with subsequent disruption of membrane
integrity, suggesting that lipid peroxidation mediated by
oxygen radicals is an important cause of damage and
destruction of cell membranes. We have shown in a model of
trinitrobenzene sulfonic acid (TNBS)-induced colitis that
thiobarbituric (TBA)-reactive substances, an index of lipid
peroxidation, significantly accumulate in the colonic mucosa
[5], and treatment with SOD led to an improvement in the
colitis score. We have also demonstrated that TBA-reactive
substances are significantly increased in the colonic mucosa
after dextran sodium sulfate (DSS) administration, and that
this increase is significantly inhibited by treatment with Mn-
SOD [6] and a synthetic vitamin E analogue [7] in the same
DSS colitis mouse model; this suggests that induction of lipid
peroxidation is an early critical event in this experimental
inflammatory bowel disease model.
In addition to direct products derived from activated
neutrophils, the secondary products induced by oxidative
stress may play a role in the development of intestinal
inflammation. Experimental and clinical evidence coming
from different laboratories suggest that 4-hydroxy-2-nonenal
(HNE, Fig. 2), a product during lipid peroxidation, can act as
bioactive molecules in either physiological or pathological
conditions. HNE can affect and modulate, at very low and
nontoxic concentrations, several cell functions, including
signal transduction, gene expression, cell proliferation, and
more generally, the response of the target cells [8–10].
Recent our preliminary study has also demonstrated HNE-
modified proteins in colonic mucosal obtained from the
patients with UC using mono- and poly-clonal antibodies
against HNE. The interaction of HNE with a variety of
kinases variously involved in cell signaling associated with
inflammation is now a matter of active investigation. In
Fig. 2. 4-Hydroxyl-2-nonenal (HNE) protein adducts as a second messengerNeutrophil-Dependent Oxidative Stress in Ulcerative Colitis
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particular, findings with regard to the effect of HNE on
different components of the protein kinase C family and the
mitogen-activated protein kinase complex already provide
reliable indications of a potential role of this aldehyde as a
cell signal messenger. Such a role appears further supported
by the clear-cut evidence of up-regulation of receptor
tyrosine kinases and down-regulation of the nuclear factor κB
system, produced by HNE concentrations actually detectable
in pathophysiology of intestinal inflammation. Recent advance
in proteomics technology makes it possible to determine
specific targets modified by oxidative stress, including
HNE. This modification of proteins may be a biomarker for
evaluation of disease activity or therapeutic efficacy.
Role of Neutrophil in Experimental Models of Colitis
Oral administration of DSS induces colitis in animals,
which histologically mimics human UC [11]. It has been
reported that the direct action of DSS on colonic epithelial
cells, macrophages, and intestinal microflora are likely to be
involved in the pathogenesis of this colitis. In addition,
recent reports have hypothesized that neutrophil-mediated
inflammation is involved in the development of DSS-
induced colonic mucosal injury. Several lines of evidence
support this hypothesis: 1) colonic mucosal endothelial
ICAM-1 expression is enhanced at an early stage in the
inflammatory cascade of DSS-induced colitis [12] and in
patients with UC [13], and immunoneutralization of ICAM-1
significantly attenuated colonic mucosal injury and neutrophil
accumulation [14], 2) numerous neutrophils accumulates in
the DSS-treated colonic mucosa, and selective depletion of
neutrophils by a monoclonal antibody reduces DSS-induced
colitis [15], and 3) scavengers or inhibitors of the neutrophil-
derived products also inhibit this type of colitis in animals
[6, 16].
Natsui et al. [15] firstly demonstrated that intraperitoneal
injections of RP-3, a monoclonal antibody capable of
selectively depleting neutrophils, significantly suppressed
bleeding, tissue myeloperoxidase activity, chemiluminescence
production and erosion formation in DSS-induced colitis
in rats. We have also shown that MPO activity, an index
of tissue-associated neutrophil accumulation, significantly
increases in the colonic mucosa after DSS administration,
and this increase is significantly inhibited by treatment with
MnSOD (Fig. 3). These results indicate that the inhibition of
neutrophil accumulation by MnSOD may be one of the
protective factors decreasing DSS-induced colonic mucosal
injury. The inhibition of neutrophil accumulation by SOD
was first reported by Grisham et al. [17] using an in vivo
model of intestinal ischemia. Recent studies have confirmed
Fig. 3.  Effects of Mn-SOD on DSS-induced colitis in mice. Acute colitis was induced by DSS administered at 8% w/v in the drinking
water in BALB/c female mice. MnSOD (50,000 U/kg) was dissolved in physiological saline, and administered by intraperitoneal
injection for 7 days. Reprinted with permission [6].Y. Naito et al.
J. Clin. Biochem. Nutr.
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that superoxide is implicated in the regulation of the endot-
helial cell adhesion molecule expression and the subsequent
initiation of leukocyte-endothelial cell adhesion in different
experimental models of inflammation.
Recently, Morohoshi et al. [16] investigated the contribution
of neutrophil elastase in a murine acute colitis model. They
have shown that the neutrophil elastase enzyme activity is
significantly elevated in both the plasma and colonic
mucosal tissue in UC patients compared with healthy
controls, and that ONO-5046, a neutrophil elastase specific
inhibitor exerts therapeutic effects in DSS-treated mice by
significantly reducing weight loss and histological score. In
addition to its protease activity contributing to tissue
destruction, it has been reported that neutrophil elastase
enhances the migration and adhesion of neutrophils [18].
ONO-5046 has already been clinically used for the treatment
of acute respiratory distress syndrome in Japan, and no
serious adverse effects have been reported. Therefore,
ONO-5046 might actually have the potential to be a new
therapeutic approach for patients with UC.
Neutrophil Activation in Ulcerative Colitis
In patients with UC, the circulating levels of neutrophils
are found to be up to three times higher than the levels
in healthy controls [19]. Morphological and functional
evidences of activation of circulating neutrophils have been
reported in patients with inflammatory bowel disease. In
1991, McCarthy et al. [20] found the increase in the number
of polarized neutrophils, determined by quantitative light
microscope examination, in patients with active stage of UC
compared to those with quiescent colitis or normal subjects.
Functionally, neutrophils obtained from UC patients have
a significantly higher response than those from controls
following phorbol myristate acetate, formyl-methionyl-
leucyl-phenylalanine, and zymosan administration [21].
Anezaki et al. [22] have investigated the correlation between
IL-8, and MPO or luminal-dependent chemiluminescence in
inflamed mucosa of UC. They have found that luminol-
dependent chemiluminescence of biopsy specimens in
active UC is markedly increased compared to those in
inactive UC and controls (Fig. 4), and that the levels of IL-8
are closely correlated to the intensity of chemiluminescence
or MPO levels. In UC, IL-8 mRNA was found mainly in
macrophages, and also in neutrophils and colonic epithelial
cells [23]. In addition, increased production of IL-8 peptides
and expression of IL-8 mRNA is observed in the inflamed
mucosa of patients with UC [24]. Since IL-8 is not only a
chemoattractive substance but also a neutrophil-activating
substance to release oxygen radicals from neutrophils, the
data by Anezaki et al. suggest that most of the infiltrating
neutrophils in the colonic mucosa of UC is activated.
Human neutrophil lipocalin (HNL) may be a more sensitive
marker for neutrophil activation in the colonic mucosa
Fig. 4. Luminol-dependent chemiluminescence in patients with ulcerative colitis. Reprinted with permission [22].Neutrophil-Dependent Oxidative Stress in Ulcerative Colitis
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compared to MPO, because primary granules including
MPO are not unique to the neutrophil granulocyte. HNL is a
secondary granule protein unique to the neutrophil. Carlson
et al. [25] have demonstrated that HNL levels in colorectal
perfusion fluids increase in ulcerative colitis and proctitis,
and suggest that HNL may serve as a specific marker of
intestinal neutrophil activation in UC.
Leukocytapheresis Therapy in Ulcerative Colitis
Leukocytapheresis procedure
The Adacolumn is an example of a medical device that can
selectively remove activated granulocytes and monocytes/
macrophages together with small populations of lymphocytes
(Fig. 5). The Adacolumn is a single use adsorptive type
apheresis column, with a volume of 335 ml, filled with 220 g
of cellulose acetate beads of 2 mm diameter as the column
adsorptive carriers. Leukocytapheresis using the Adacolumn
is performed in out-patient clinic for patients with mild to
moderate symptoms, and patients with severe symptoms
were hospitalized for apheresis. The process of performing
leukocytapheresis is relatively simple. Prior to apheresis,
the system is primed by saline-containing anticoagulant,
nafamostat mesilate or heparin, and during apheresis saline
containing those anticoagulants is continuously administered
into the column. The commonly used apheresis time and
blood flow rate are 60 min and 30 ml/min, respectively.
During these procedures, the carriers absorb about 65% of
granulocytes, 55% of monocytes and 2% of lymphocytes
from the blood in the column. These are the leukocytes that
bear the so-called FcgR and complement receptors. One
apheresis session per week for five consecutive weeks has
been a standard protocol. Recently, other protocols with two
sessions per week or a total of 10 apheresis sessions have
been used for patients with severe UC.
Anti-inflammatory/immunomodulatory actions of the Ada-
column
Although the aim of treatment with Adacolumn has been
to remove excess and activated granulocytes and monocytes
from the circulation, recent reports have demonstrated the
anti-inflammatory and immunomodulatory actions of this
leukocytaheresis. At first, during passage of blood through
the Adacolumn, most of the activated leukocytes adhere to
the cellulose acetate beads. In the intra-column response, the
adhered leukocytes release an array of anti-inflammatory
substances. It has been found the increase in interleukin-10
[26], soluble tumor necrosis factor (TNF)-α receptor I and II
[27], interleukin-1 receptor antagonist, and hepatocyte
growth factor (HGF) [28]. Soluble TNF-α receptors are
reported to neutralize TNF without involving TNF-like
actions. IL-1ra has an essential role in the control of
inflammation in the intestinal mucosa, while HGF is known
to promote mucosal epithelial cell regeneration. Secondary,
Fig. 5.  Electron micrograph showing leukocytes, mostly neutrophils and monocytes adsorbed onto an Adacolumn cellulose acetate carrier.
Photograph by Dr. A. Saniabadi of Japan Immunoresearch Laboratories.Y. Naito et al.
J. Clin. Biochem. Nutr.
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the expression of both L-selectin and the chemokine
receptor CXCR3 were dramatically reduced and were
sustained well beyond the last leukocytapheresis session
[29, 30], whereas the expression of the leukocyte integrin
Mac-1 (CD11b/CD18) was upregulated. Finally, a study by
Kashiwagi et al. [30] shows that the proportion of naïve or
immature neutrophils (CD10− neutrophils) in the circulation
significantly increases during Adacolumn leukocytapheresis,
indicating that immature granulocytes had originated from
the bone marrow.
Indications for leukocytapheresis
According to the Guideline of the Investigation and
Research Committee of Inflammatory Bowel Disease of the
Ministry of Health and Welfare of Japan, leukocytapheresis
has been mainly used for patients with steroid-refractory
and steroid-dependent moderate-to-severe UC. Recently,
steroid-naïve patients with mild UC were also treated with
leukocyte apheresis.
Clinical efficacy
Recently, Yamamoto et al. summarized the safety and
clinical efficacy of leukocytapheresis using the Adacolumn
(granulocyte and monocyte adsorptive apheresis: GMCAP)
for ulcerative colitis. The efficacy of GMCAP was evaluated
using clinical activity index or disease activity index scores
[31]. In a prospective multicenter trial in Japan, 53 patients
refractory to conventional drug therapy were treated with the
standard GMCAP protocol (five apheresis sessions for five
consecutive weeks) in combination with prednisolone. After
the treatment, 21% and 37% of patients achieved remission
and improvement, respectively, and the mean daily dose of
prednisolone per patients was reduced from 24.4 mg at
enrollment to 14.2 mg after GMCAP therapy. In addition to
steroid-refractory UC patients, it has been shown that 88%
of steroid-naive patients achieved remission by GMCAP
therapy [32]. In summary, clinical data obtained in Japan
suggest that leukocytapheresis is an effective adjunct to
therapy for UC to promote remission, taper conventional
drug dosage, and potentially reduce the number of patients
who require colectomy. The results should further under-
standing of the pathophysiology of inflammatory bowel
disease.
Conclusions
We have summarized the recent advances in the role
of neutrophils-dependent oxidative stress in intestinal
inflammation of UC. Although basic research has
demonstrated that several antioxidants and inhibitors of
neutrophils-derived enzymes inhibit the inflammatory
responses in intestinal tracts, further studies will be needed
to clarify the precise mechanism of these agents. In
clinically, the successful outcome of leukocytapheresis for
UC clearly confirms the crucial role of neutrophils in the
pathogenesis of this disease.
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